Aerovate Q3 net loss widens to $13.6M; trial enrollment delays, cash runway to 2H25

Jade Biosciences, Inc.

2022-Q3 EPS reported -$1.49

Net loss $13.6M for Q3 2022 vs $6.2M in Q3 2021; R&D expenses tripled to $10.8M.
Cash and investments $142.6M as of Sep 30, 2022, down from $167.4M at Dec 31, 2021; runway into 2H25.
IMPAHCT Phase 2b/3 trial enrollment delayed; topline data expected Q4 2023 or Q1 2024.
Expanded IP with two new U.S. patents (11,413,289 and 11,464,776) issued; notice of allowance for another.
Sanjeev Khindri joined as SVP Clinical Development; brings respiratory and PAH experience.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jade Biosciences, Inc. reported the quarter ended September 30, 2022 results: net income $13.6 million.

Period: the quarter ended September 30, 2022
Net income: $13.6 million
Result: reported results

Exact text from the filing

On November 14, 2022, Aerovate Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-017582

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.